Novartis Dives Into Inflammasome Pool With IFM Tre Purchase
Executive Summary
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
You may also be interested in...
Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing
The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.